Astragaloside IV (AS-IV) alleviates HF by inhibiting CCL2-mediated NF-κB signaling pathway activation, reducing LPS-induced myocardial hypertrophy and collagen deposition (35). Here, CCL2 is linked to cardiac hypertrophy.